Search
daprodustat (Jesduvroq)
Indications:
- treatment of anemia in renal dialysis patients (FDA-approved)*
- oral alternative to conventional erythropoiesis-stimulating agents
* not approved for patients not on renal dialysis
* patients must be on renal dialysis for at least 4 months [2]
Dosage:
- start 4-12 mg PO QD depending upon prior does of erythropoiesis-stimulating agent
- adjust to blood hemoglobin 10-11 g/dL
- maximum 24 mg QD
Mechanism of action:
- hypoxia-inducible factor prolyl hydroxylase inhibitor
General
hematologic agent
Database Correlations
PUBCHEM cid=91617630
References
- Singh AK et al.
Daprodustat for the treatment of anemia in patients undergoing dialysis.
N Engl J Med 2021 Dec 16; 385:2325
PMID: 34739194
https://www.nejm.org/doi/10.1056/NEJMoa2113379
- Singh AK et al.
Efficacy and safety of daprodustat for treatment of anemia of
chronic kidney disease in incident dialysis patients:
A randomized clinical trial.
JAMA Intern Med 2022 Apr 4; [e-pub].
PMID: 35377393 PMCID: PMC8981070 Free PMC article
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2790862
- Monaco K
FDA Panel Gives Thumbs Up to Anemia Pill for CKD Patients on Dialysis.
But thumbs quickly turn down for the non-dialysis subset.
MedPage Today October 27, 2022
https://www.medpagetoday.com/nephrology/anemia/101450
- Zoler ML
FDA Approves Daprodustat, First Oral Anemia Treatment.
Medscape. Feb 2, 2023
https://www.medscape.com/viewarticle/987789